Highlights Pharmala Biotech Holdings Inc.

Equities

MDMA

CA71719L1067

Market Closed - Canadian Securities Exchange Other stock markets 20:08:27 16/05/2024 BST			5-day change	1st Jan Change
0.185 ^CAD	0.00%		-2.63%	+32.14%

05-03	PharmAla Up Near 8% As Launches Prescriber's Portal for Medical Professionals Focused on MDMA Therapy	MT
04-23	Red Light Holland Corp. Initiates Psilocybin Extraction Phase with PharmAla	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

PharmAla Up Near 8% As Launches Prescriber's Portal for Medical Professionals Focused on MDMA Therapy	05-03	MT
Red Light Holland Corp. Initiates Psilocybin Extraction Phase with PharmAla	04-23	CI
Pharmala Biotech Completes $750,000 Private Placement, Debt Settlement	04-19	MT
PharmAla Biotech Provides Australian Update	04-05	MT
Pharmala Biotech Holdings Inc. Allowance Granted for Ala-002 Composition by US Patent and Trademark Office	03-27	CI
Pharmala Biotech Holdings Inc. Signs Sale Agreement with Numinus	03-26	CI
PharmAla Says Patent Allowance Granted for P-1 Molecule by USPTO	03-20	MT
Pharmala Biotech Holdings Inc. Announces Patent Allowance Granted for P-1 Molecule by US Patent and Trademark Office	03-20	CI
PharmAla Biotech Holdings Inc. Announces Joint Venture with Cortexa Pty. Ltd	03-18	CI
PharmAla Biotech Holdings Inc. Announces Data from its Computational Drug Discovery Program in the Scientific Journal ACS Chemical Neuroscience	02-20	CI
Listed Duo PharmAla and Red Light Holland to Collaborate on Medical Psilocybin Development	02-09	MT
PharmAla Biotech Holdings Inc. Enters into Consulting Relationship with Red Light Holland Corp	02-09	CI
PharmAla Reports Q1 Profit, Provides Business Update	01-31	MT
PharmAla up 41%, Granted Controlled Drugs & Substances Dealer's License by Health Canada	01-25	MT
Pharmala Biotech Holdings Inc.'s PharmAla-1 Molecule Receives US Patent Prosecution Highway Acceptance	01-08	CI
PharmAla Biotech Holdings Inc. Announces World's First Observational Trial to Assess Real-World Efficacy of MDMA Treatment	11-09	CI
PharmAla Biotech Received First Office Action for PharmAla-1 PCT Filing	25/09/23	MT
Pharmala Biotech Holdings Inc. Receives First Office Action for PharmAla-1 Pct Filing	25/09/23	CI
PharmAla Biotech Holdings Inc. Ships GMP LaNeo Efficacy to Mind Medicine Australia	10/08/23	CI
PharmAla Biotech Filed Patent for Novel MDXX Molecule PharmAla-1	31/07/23	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Pharmala Biotech Holdings Inc.

Equities

MDMA

CA71719L1067

Highlights

Filters